HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy.

Abstract
Five patients with severe dysthyroid optic neuropathy were treated with intravenous methylprednisolone (1 g daily for 3 consecutive days). Before administration, visual acuity of the more severely affected eyes of each patient was counting fingers at 5 feet, 8/200, 20/400, 20/200, and 20/80. Immediately after completion of pulse therapy, visual acuity improved to 20/25 in four patients and 20/30 in one. Remissions were maintained with oral prednisone and external beam irradiation of the orbit. Pulse methylprednisolone therapy appears to be beneficial in the initial management of severe dysthyroid optic neuropathy.
AuthorsJ R Guy, S Fagien, J P Donovan, M L Rubin
JournalOphthalmology (Ophthalmology) Vol. 96 Issue 7 Pg. 1048-52; discussion 1052-3 (Jul 1989) ISSN: 0161-6420 [Print] United States
PMID2771352 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Hydrochlorothiazide
  • Methylprednisolone
Topics
  • Adult
  • Female
  • Graves Disease (drug therapy)
  • Humans
  • Hydrochlorothiazide (administration & dosage)
  • Hypertension (drug therapy)
  • Injections, Intravenous
  • Magnetic Resonance Imaging
  • Male
  • Methylprednisolone (therapeutic use)
  • Middle Aged
  • Orbit (radiation effects)
  • Tomography, X-Ray Computed
  • Visual Acuity
  • Visual Fields

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: